Komori
Mochida Pharmaceutical (4534) · InitiativeRestated

Performance-Linked Compensation and Share Ownership through an Executive Stock Ownership Association

First written in FY2021. 3 of 4 entries say "Restated". Latest entry: FY2026.

4entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2021 – FY20262021: 120212022: 120222023: 020232024: 020242025: 120252026: 12026
Same theme, other companies
Medium- to long-term incentives through performance-linked compensation and executive share ownershipA theme 9 companies write about · 0 as a headwind · 9 as a tailwind

The whole theme swung hardest in 2019: 1 of 6 companies on the "Worse" side.

2 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「Directors’ remuneration consists of monthly remuneration, which is fixed remuneration, and bonuses, which are performance-linked remuneration. The ratio of fixed remuneration (monthly remuneration) to performance-linked remuneration (bonuses) is set at a level that the Company considers appropriate to function as an incentive to enhance corporate value.」

    The company has reaffirmed its policy of combining fixed compensation with performance-linked compensation and continuing to purchase shares through the officers' shareholding association.
  2. FY2025RestatedAnnual report

    「Directors’ remuneration consists of monthly remuneration, which is fixed remuneration, and bonuses, which are performance-linked remuneration. The ratio of fixed remuneration (monthly remuneration) to performance-linked remuneration (bonuses) is set at a level that the Company considers appropriate to function as an incentive to enhance corporate value.」

    The company reaffirms its policy of combining fixed and performance-linked remuneration and continuing to acquire and hold shares through the officers’ shareholding association.
  3. FY2022RestatedAnnual report

    「Directors’ remuneration consists of monthly remuneration, which is fixed remuneration, and bonuses, which are performance-linked remuneration. The ratio of fixed remuneration (monthly remuneration) to performance-linked remuneration (bonuses) is set at a level that the Company considers appropriate to function as an incentive to enhance corporate value.」

    The company continues its remuneration policy of combining fixed and performance-linked remuneration and holding shares through the officers’ shareholding association.
  4. FY2021First statedAnnual report

    「Directors’ remuneration consists of monthly remuneration, which is fixed remuneration, and bonuses, which are performance-linked remuneration. The ratio of fixed remuneration (monthly remuneration) to performance-linked remuneration (bonuses) is set at a level that the Company considers appropriate to function as an incentive to enhance corporate value.」

    The company discloses a remuneration structure combining fixed and performance-linked remuneration, with officers continuing to acquire and hold shares through the officers’ shareholding association.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Mochida Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Performance-Linked Compensation and Share Ownership through an Executive Stock Ownership Association | Mochida Pharmaceutical Co.,Ltd. (4534) | Komori